Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
David R AndesMahmoud A GhannoumPranab K MukherjeeLaura Lynn KovandaQiaoyang LuMark E JonesAnne Santerre HenriksenChristopher LademacherWilliam W HopePublished in: Antimicrobial agents and chemotherapy (2018)
This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.